Indietro

Oral Communication

Virology and pharmacology across the spectrum of HIV treatment

OC 16
Do low-frequency drug-resistant HIV-1 variants have a role on first-line INSTI-containing regimens? A case-control study from the ICONA cohort
Abstract
OC 17
Long Acting Cabotegravir and Rilpivirine plasma and intracellular pharmacokinetics in the Clinical Setting
Abstract
OC 18
Network analysis of proviral DNA mutations in People with 4-class-resistant HIV-1: Data from the PRESTIGIO Registry
Abstract
OC 19
The in vitro genetic barrier to resistance of lenacapavir is not affected by viral subtype or heavy treatment exposure
Abstract
| Privacy policy | Cookies policy | Termini e condizioni di utilizzo |
© Effetti srl
P. IVA 10756900154
×

Commento audio

Chiudi